Lexicon Pharmaceuticals, Inc. (LXRX)

Oncology Corporate Profile

Stock Performance

13.9400
-0.2200

HQ Location

8800 Technology Forest Place
The Woodlands, TX 77381

Company Description

Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism.

Website: http://www.lexpharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
telotristat etiprate / LX1032tryptophan hydroxylase inhibitorVarious cancer typesIII

View additional information on product candidates here »

Source: http://www.lexpharma.com

Recent News Headlines

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/4/2017 12:18 pm

5/2/2017 12:18 pm

4/28/2017 12:18 pm

4/26/2017 12:18 pm

4/26/2017 12:18 pm